X4 Pharmaceuticals (XFOR) EBT (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly EBT came in at -$23.9 million in Q4 2025, up 39.53% YoY from -$17.1 million in Q4 2024, and up 19.84% on a QoQ basis from -$29.8 million in Q3 2025.
X4 Pharmaceuticals (XFOR) EBT (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of EBT data on file, last reported at -$23.9 million in Q4 2025.
- Quarterly EBT rose 39.53% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 113.13% YoY) and the FY2025 annual result came in at -$79.2 million, down 113.13% from the prior year.
- EBT grew to -$23.9 million in Q4 2025, from -$29.8 million in the prior quarter.
- In the past five years, EBT ranged from a high of $90.9 million in Q2 2024 to a low of -$55.7 million in Q2 2023.
- A 5-year average of -$20.0 million and a median of -$22.9 million in 2022 frame the typical range for EBT.
- The widest YoY moves for EBT: up 263.12% in 2024, down 1509.52% in 2024.
- Tracing XFOR's EBT over 5 years: stood at -$30.2 million in 2021, then advanced by 3.69% to -$29.1 million in 2022, then surged by 34.35% to -$19.1 million in 2023, then tumbled by 107.17% to -$39.6 million in 2024, then surged by 39.53% to -$23.9 million in 2025.
- The last three EBT figures came in at -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | -16.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16 Mn |
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.85 Mn |
| Jun 30, 2025 | -25.70 Mn |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | -39.56 Mn |
| Sep 30, 2024 | -36.68 Mn |
| Jun 30, 2024 | 90.85 Mn |
| Mar 31, 2024 | -51.75 Mn |
| Dec 31, 2023 | -19.10 Mn |
| Sep 30, 2023 | -2.28 Mn |
| Jun 30, 2023 | -55.70 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.09 Mn |
| Sep 30, 2022 | -21.60 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.94 Mn |
| Dec 31, 2021 | -30.20 Mn |
| Sep 30, 2021 | -20.17 Mn |
| Jun 30, 2021 | -19.63 Mn |